NEW YORK, July 8-A Japanese pharmaceutical development consortium will use Biacore's newest system for analyzing drug/protein interactions, the company said today.
The Reverse Proteomics Research Institute consortium, which includes 11 Japanese pharmaceutical companies, was founded in May 2001. It is currently engaged in a project to study the interactions between 800 small molecules and 6,000 cDNA-derived human proteins. The effort is funded by the member companies and by the Japanese economic ministry.
The Biacore system, S51, supplies data on binding kinetics, drug/target affinity, and reaction specificity for lead optimization and pre-clinical drug candidate studies.
Biacore, which develops tools for life science research, is based in Uppsala, Sweden.